Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pregabalin→

Pregabalin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
148553-50-8
Molecular formula
C8H17NO2
Molecular weight
159.23 g/mol
Drug class
Gabapentinoidligand of the alpha-2-delta subunit of voltage-gated calcium channels
Mechanism of action
Binds with high affinity to the alpha-2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system, reducing calcium influx and release of excitatory neurotransmitters. It is not a direct GABA receptor agonist.
Indications / reported uses
  • Neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia and spinal cord injury in adults, according to product label
  • Adjunctive treatment of partial-onset seizures in eligible patients
  • Fibromyalgia in adults under the US product indication; use for other pain syndromes may be off-label and jurisdiction-specific

Sources: US DailyMed — Pregabalin · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pregabalin Environmental Risk Assessment (ERA) (the Pregabalin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.